A phase 1, randomized, placebo-controlled, double blind, dose-escalation, multicenter study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single intravenous dose of PF-04360365 in Japanese patients with mild to moderate Alzheimer's disease.

Trial Profile

A phase 1, randomized, placebo-controlled, double blind, dose-escalation, multicenter study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single intravenous dose of PF-04360365 in Japanese patients with mild to moderate Alzheimer's disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2013

At a glance

  • Drugs Ponezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Preliminary tolerability outcomes were reported at the 2010 International Conference on Alzheimer's Disease.
    • 15 Jul 2010 Preliminary pharmacokinetic results were reported at the 2010 International Conference on Alzheimer's Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top